India's tax authorities confirm ₹155 crore GST demand on Aurobindo Pharma
Change
India's Principal Commissioner of Customs and Central Tax (Appeals I), Hyderabad confirmed a combined GST demand, interest and penalty totalling ₹155,22,70,484 — including a ₹77,61,35,242 GST shortfall and an equal penalty — over alleged excess IGST refunds and non-reversal of input tax credit on exports from July 1, 2017 to March 23, 2020.
Why it matters
The confirmation makes the assessed tax and penalty an enforceable liability that can be collected unless an appellate stay is obtained. Corporate treasury and tax teams must therefore allocate liquidity or secure tribunal relief to prevent enforcement and running interest while the matter is contested.
Implications
- • Aurobindo Pharma's tax and finance teams must provision or pay the outstanding demand and penalties to avoid enforcement action and additional interest being levied.
- • Aurobindo Pharma's legal and tax teams must file an appeal at the Goods and Services Tax Appellate Tribunal (GSTAT) and seek a stay order if they intend to suspend collection while contesting the assessment.
Unlock the decision layer.
Go beyond headlines — see impact, exposure, and timing.
- Implications: What actually changes downstream.
- Who is affected: Which teams or operators are exposed.
- What to watch: Deadlines, triggers, and next moves.
- Real-time alerts: Know the moment a change is published.
- Ask AI: Clarify any brief instantly, in context.
14-day free trial. Full access. No credit card required.
Start free trial
Source
Topics